{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:00:43Z","timestamp":1791381643546,"version":"4.3.3"},"reference-count":107,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"abstract":"<jats:title>\n                    <jats:bold>SUMMARY<\/jats:bold>\n                  <\/jats:title>\n                  <jats:p>\n                    The treatment and prevention of HIV have undergone significant transformations in the 16 years since the last major review of HIV therapeutics published in ASM\u2019s\n                    <jats:italic toggle=\"yes\">Journal of Virology<\/jats:italic>\n                    (A. M. N. Tsibris and M. S. Hirsch, J Virol 84:5458\u20135464, 2010,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1128\/jvi.02524-09\" xlink:type=\"simple\">https:\/\/doi.org\/10.1128\/jvi.02524-09<\/jats:ext-link>\n                    ). First-generation antiretroviral medications, many now discontinued, have been replaced by integrase strand transfer inhibitor-based regimens that offer superior efficacy, higher genetic barriers to resistance, and the convenience of a single-tablet fixed-dose combination. Dolutegravir and bictegravir are now the anchors of most first-line therapies worldwide, and two-drug and nucleoside reverse transcriptase inhibitor (NRTI)-sparing strategies have emerged, allowing for simplification of treatment of patients who had been previously on complex regimens. The most consequential recent advance, though, has been the introduction of long-acting injectable medications, including cabotegravir-rilpivirine for treatment, standalone cabotegravir for pre-exposure prophylaxis (PrEP), and lenacapavir, a first-in-class capsid inhibitor for both treatment and PrEP. For people with multidrug-resistant HIV, new agents including fostemsavir, ibalizumab, and lenacapavir have made virologic suppression achievable in virtually all heavily treatment-experienced patients. An investigational and emerging pipeline that includes third-generation integrase inhibitors, nucleoside reverse transcriptase translocation inhibitors, maturation inhibitors, and broadly neutralizing antibodies promises further expansion of HIV therapeutic options. These advances, however, come with potential challenges, including emergent resistance to long-acting agents, metabolic consequences of lifelong therapy in an aging population, persistent inequities in global access to newer agents, and often insufficient safety data in pregnancy and breastfeeding. This review provides a clinical assessment of the current antiretroviral options, from legacy agents to investigational therapies, with attention to the resistance, implementation, and special population considerations that will shape HIV practice in the future.\n                  <\/jats:p>","DOI":"10.1128\/cmr.00163-24","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:01:49Z","timestamp":1790773309000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["HIV therapeutics in 2026"],"prefix":"10.1128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-6245","authenticated-orcid":true,"given":"Danilo","family":"Bacic Lima","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05cf8a891","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine","place":["Bronx, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-0571","authenticated-orcid":true,"given":"Yijia","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Medicine, University of Pittsburgh","place":["Pittsburgh, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Cherabie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01yc7t268","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-9021","authenticated-orcid":true,"given":"Carlos S.","family":"Saldana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03czfpz43","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Emory University School of Medicine","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707233170401"},{"key":"e_1_3_3_3_2","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori V","year":"2004","unstructured":"Montessori V, Press N, Harris M, Akagi L, Montaner JSG. 2004. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170:229\u2013238.","journal-title":"CMAJ"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02524-09"},{"key":"e_1_3_3_5_2","unstructured":"Department of Health and Human Services. 2025. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv. Retrieved 5 Apr 2026."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7401a1"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30418-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30132-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_3_14_2","unstructured":"World Health Organization. 2025. WHO updated recommendations on HIV clinical management: recommendations for a public health approach. Geneva. https:\/\/www.who.int\/publications\/i\/item\/9789240119468."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_3_17_2","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre JM","year":"2015","unstructured":"Llibre JM, Pulido F, Garc\u00eda F, Garc\u00eda Deltoro M, Blanco JL, Delgado R. 2015. Genetic barrier to resistance for dolutegravir. AIDS Rev 17:56\u201364.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30702-8"},{"key":"e_1_3_3_19_2","unstructured":"World Health Organization. 2024. HIV drug resistance: brief report 2024. Geneva World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789240086319."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00307-7"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00092-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30036-2"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210005"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00130-4"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf098"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902824"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0293"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00258-8"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02650-15"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf039"},{"key":"e_1_3_3_32_2","unstructured":"Chelsea and Westminster NHS Foundation Trust. 2023. Efficacy of doravirine + dolutegravir dual therapy in the context of antiretroviral therapy switch (DORDOL). NCT04892654. Clinical trial registration. clinicaltrials.gov"},{"key":"e_1_3_3_33_2","volume-title":"Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States","author":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission","year":"2026","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. 2026. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1103"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01229-9"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d7350"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61049-6"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00089-4"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062744"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002857"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003395"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf135"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac610"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf100"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag061"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002449"},{"key":"e_1_3_3_49_2","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Meissner E","year":"2026","unstructured":"Meissner E, Ramgopal MN, Ruane PJ, Sanchez WE, Routy J-P, O\u2019Reilly M, Lupo S, Schellberg S, Aizen K, Huang H, Mponponsuo K, Sklar P, Rhee M, Hung C-C. 2026. Phase III efficacy and safety of switch from B\/F\/TAF to single-tablet BIC\/LEN in ARTISTRY-2, p. abstract 513. Conference on Retroviruses and Opportunistic Infections (CROI)."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00184-3"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf161"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003448"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02929-8"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002883"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508228"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2985"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag392"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2402088"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab576"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00053-23"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf763"},{"key":"e_1_3_3_69_2","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Ndlovu N","year":"2026","unstructured":"Ndlovu N. 2026. Twice-yearly subcutaneous lenacapavir for PrEP: updated HIV-1 incidence and safety data in purpose 1, p. Abstract 128. Conference on Retroviruses and Opportunistic Infections (CROI). . https:\/\/www.croiconference.org\/abstract\/557-2026."},{"key":"e_1_3_3_70_2","unstructured":"Lucio VDC. 2026 Lenacapavir for PrEP: HIV-1 incidence and safety from PURPOSE 2 at end of randomized blinded phase. Abstract 129. CROI Conf 2026. https:\/\/www.croiconference.org\/abstract\/545-2026."},{"key":"e_1_3_3_71_2","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Cox S","year":"2026","unstructured":"Cox S, Andreatta K, Hendricks MR, Li J, Puryear S, Hojilla JC, Carter CC, Callebaut C. 2026. Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase. Abstract 130. Conference on Retroviruses and Opportunistic Infections (CROI). https:\/\/www.croiconference.org\/abstract\/362-2026\/."},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00405-2"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00870-6"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/20499361251325103"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq261"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105427"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf135"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag357"},{"key":"e_1_3_3_82_2","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Hansen D","year":"2025","unstructured":"Hansen D. 2025. In vitro resistance profile for GS-1720, a potent once-weekly oral INSTI in clinical development, p. Abstract 724. Conference on Retroviruses and Opportunistic Infections (CROI). . https:\/\/www.natap.org\/2025\/CROI\/croi_08.htm."},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00329-7"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01129-y"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103567"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103566"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050594"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101283"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00293-X"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf375"},{"key":"e_1_3_3_91_2","volume-title":"Maintenance of HIV suppression at 12 months with lotivibart (VH3810109, N6LS) Q4M + CAB LA QM: the EMBRACE study","author":"Rolle C-P","year":"2026","unstructured":"Rolle C-P. 2026 Maintenance of HIV suppression at 12 months with lotivibart (VH3810109, N6LS) Q4M + CAB LA QM: the EMBRACE study"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac835"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.562694"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00133-22"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiag257"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2607973"},{"key":"e_1_3_3_97_2","unstructured":"Sharp M Dohme LLC. 2026. A phase 3 randomized active-controlled double-blind clinical study to evaluate the efficacy and safety of MK-8527 oral once-monthly as HIV-1 preexposure prophylaxis. NCT07044297. Clinical trial registration. clinicaltrials.gov"},{"key":"e_1_3_3_98_2","volume-title":"Denver, CO. Conference on Retroviruses and Opportunistic Infections (CROI","author":"Kapoor Y","year":"2026","unstructured":"Kapoor Y, Skataric M, Vargo R, Carstens RP, Stamm LM, Plank RM. 2026. MK-8527 phase 3 dose selection for monthly oral HIV-1 pre-exposure prophylaxis, p. Abstract 126. Denver, CO. Conference on Retroviruses and Opportunistic Infections (CROI."},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)01442-X"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00031-6"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf077"},{"key":"e_1_3_3_102_2","unstructured":"U.S. Food and Drug Administration. 2026. Idvynso (doravirine and islatravir) tablets: prescribing information"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004367"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004332"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002834"},{"key":"e_1_3_3_106_2","volume-title":"26th International AIDS Conference, Rio de Janeiro","author":"Luetkemeyer A","year":"2026","unstructured":"Luetkemeyer A et al.. 2026. Randomized, active-controlled, phase 2b study evaluating efficacy and safety of switch to islatravir (ISL) 2 mg with ulonivirine ULO) 200 mg once weekly in virologically suppressed adults living with HIV-1, p. Abstract OAB1405LB, p. 26th International AIDS Conference, Rio de Janeiro"},{"key":"e_1_3_3_107_2","volume-title":"Lenacapavirdrugs and lactation database (LactMed)","year":"2006","unstructured":"Lenacapavirdrugs and lactation database (LactMed). 2006. National Institute of Child Health and Human Development, Bethesda (MD)."},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cmr.00163-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cmr.00163-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:45:56Z","timestamp":1791380756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/cmr.00163-24"}},"subtitle":[],"editor":[{"given":"Jacinda","family":"Abdul-Mutakabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":107,"alternative-id":["10.1128\/cmr.00163-24"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00163-24","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00163-24"}}